PL3137102T3 - Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry - Google Patents

Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry

Info

Publication number
PL3137102T3
PL3137102T3 PL14889425T PL14889425T PL3137102T3 PL 3137102 T3 PL3137102 T3 PL 3137102T3 PL 14889425 T PL14889425 T PL 14889425T PL 14889425 T PL14889425 T PL 14889425T PL 3137102 T3 PL3137102 T3 PL 3137102T3
Authority
PL
Poland
Prior art keywords
apc
treatment
cutaneous scarring
abnormal cutaneous
abnormal
Prior art date
Application number
PL14889425T
Other languages
English (en)
Inventor
Christopher John Jackson
Meilang Xue
Original Assignee
Zz Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901397A external-priority patent/AU2014901397A0/en
Application filed by Zz Biotech Llc filed Critical Zz Biotech Llc
Publication of PL3137102T3 publication Critical patent/PL3137102T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL14889425T 2014-04-16 2014-10-29 Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry PL3137102T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring
PCT/AU2014/050323 WO2015157791A1 (en) 2014-04-16 2014-10-29 Treatment of abnormal cutaneous scarring
EP14889425.6A EP3137102B1 (en) 2014-04-16 2014-10-29 Apc for use in the treatment of abnormal cutaneous scarring

Publications (1)

Publication Number Publication Date
PL3137102T3 true PL3137102T3 (pl) 2022-02-07

Family

ID=54323254

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14889425T PL3137102T3 (pl) 2014-04-16 2014-10-29 Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry

Country Status (11)

Country Link
US (3) US20170042982A1 (pl)
EP (1) EP3137102B1 (pl)
JP (2) JP2017513944A (pl)
CN (1) CN106573040B (pl)
AU (1) AU2014391082B2 (pl)
CA (1) CA2946028C (pl)
DK (1) DK3137102T3 (pl)
ES (1) ES2890675T3 (pl)
PL (1) PL3137102T3 (pl)
PT (1) PT3137102T (pl)
WO (1) WO2015157791A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas
EP3941495A4 (en) 2019-03-19 2022-09-07 Figene, LLC TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY AND PULMONARY DEGENERATION USING ACTIVATED FIBROBLASTS AND EXOSOME DERIVATIVES THEREOF
CN113073082A (zh) * 2021-03-19 2021-07-06 广州远想生物科技有限公司 TGF-β3间充质干细胞外泌体及其制备方法和应用
CN114788711A (zh) * 2022-04-26 2022-07-26 李娜 一种瘢痕评估方法及系统

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインc調製物及びその製法
AU2467395A (en) 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
ATE298246T1 (de) * 2000-03-28 2005-07-15 Lilly Co Eli Aktiviertes protein c zur behandlung von pankreatitis
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
EP1404412B1 (en) * 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DK1477166T3 (da) * 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
WO2005007820A2 (en) * 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
ZA200800255B (en) 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
US20100284997A1 (en) * 2006-10-31 2010-11-11 Griffin John H Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
WO2014005183A1 (en) * 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas

Also Published As

Publication number Publication date
ES2890675T3 (es) 2022-01-21
CA2946028C (en) 2022-10-11
EP3137102A4 (en) 2017-12-20
EP3137102A1 (en) 2017-03-08
JP2017513944A (ja) 2017-06-01
DK3137102T3 (da) 2021-10-11
US20170042982A1 (en) 2017-02-16
WO2015157791A1 (en) 2015-10-22
US11491214B2 (en) 2022-11-08
US20190060421A1 (en) 2019-02-28
CA2946028A1 (en) 2015-10-22
EP3137102B1 (en) 2021-07-14
US20200108128A1 (en) 2020-04-09
CN106573040A (zh) 2017-04-19
PT3137102T (pt) 2021-09-28
CN106573040B (zh) 2021-07-06
AU2014391082A1 (en) 2016-11-03
JP6846063B2 (ja) 2021-03-24
JP2020023519A (ja) 2020-02-13
AU2014391082B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
GB2526267B (en) Dressing for surgical drain
SG11201607705XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP3151797A4 (en) Methods and devices for treating the skin
IL244182B (en) Preparations, methods and systems for the treatment of skin disorders
PT2896395T (pt) Formulação para o tratamento de feridas tópicas
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP3215157B8 (en) Apilimod for use in the treatment of melanoma
EP3139927A4 (en) Wound healing using braf inhibitors
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3108840A4 (en) Electric surgical treatment system
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
EP3094451A4 (en) Reduced-vibration surface treatment device
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
PL3137102T3 (pl) Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
EP3007834A4 (en) Device for, or in, the surface treatment of objects
IL246855A0 (en) Materials for use in the treatment of retinitis
IL244871B (en) Laser treatment device
EP3175809A4 (en) Laser medical treatment device
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
PL3131572T3 (pl) Analog apc do zastosowania w zaleczaniu rany
PL3194634T3 (pl) Urządzenie mocujące do obróbki powierzchniowej noży sztabkowych
PT3104872T (pt) Paricalcitol para uso no tratamento de anemia inflamatória
AU2014901397A0 (en) Treatment of abnormal cutaneous scarring
AU2014902732A0 (en) Treatment and prophylaxis
AU2014902075A0 (en) New Therapeutic Treatment Combination